0000000000175232

AUTHOR

D. Farina

showing 6 related works from this author

Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis

2004

BACKGROUND: Cognitive impairment may occur at any time during the course of multiple sclerosis (MS), and it is often a major cause of disability in patients with the disease. The APOE-epsilon4 allele is the major known genetic risk factor for late onset familial and sporadic Alzheimer's Disease (AD), and it seems to be implicated in cognitive decline in normal elderly persons. OBJECTIVE: To investigate the clinical and genetic variables that can be associated with the cognitive decline in patients with MS. METHODS: Five-hundred and three patients with clinically definite MS underwent a battery of neuropsychological tests and, according to the number of failed tests, were divided into cognit…

Apolipoprotein EAdultMalemedicine.medical_specialtyPediatricsNeurologyMultiple SclerosisMessengerLate onsetDiseaseNeuropsychological TestsApolipoproteins EmedicineOdds RatioHumansRNA MessengerCognitive declineAllelePsychiatrycognitive impairmentAPOE; Cognitive impairment; Multiple sclerosisAnalysis of VarianceSex CharacteristicsChi-Square DistributionReverse Transcriptase Polymerase Chain ReactionMultiple sclerosisCognitive disorderGenetic VariationMiddle Agedmedicine.diseasemultiple sclerosis cognitive impairment gender geneticNeurologyGenetic Variation; Odds Ratio; Analysis of Variance; Sex Characteristics; Chi-Square Distribution; Humans; Apolipoproteins E; Reverse Transcriptase Polymerase Chain Reaction; Cognition Disorders; RNA Messenger; Multiple Sclerosis; Adult; Middle Aged; Neuropsychological Tests; Female; MaleRNAFemaleSettore MED/26 - NeurologiaNeurology (clinical)Psychologymultiple sclerosis · cognitive impairment · APOECognition DisordersAPOE
researchProduct

Cognitive dysfunction in patients with relapsing-remitting multiple sclerosis

2006

Cognitive dysfunction is considered one of the clinical markers of multiple sclerosis (MS). However, in the literature there are inconsistent reports on the prevalence of cognitive dysfunction, and separate data for the relapsing-remitting (RR) type of the disease are not always presented. In this study, we submitted 461 RRMS patients to a battery of neuropsychological tests to investigate their impairment in various cognitive domains. As a consequence of the exclusion criteria, the sample is not fully representative of the entire population of RRMS patients. In this selected sample, when only the eight scores of a core battery (Mental Deterioration Battery) were considered (with respectiv…

Adult050103 clinical psychologymedicine.medical_specialtyMultiple Sclerosismultiple sclerosis cognition single digit modality test information processingNeuropsychological TestsAudiologyDevelopmental psychology03 medical and health sciencesCognitionMultiple Sclerosis Relapsing-Remitting0302 clinical medicineMemoryOutpatientsOutpatients; Humans; Patient Selection; Multiple Sclerosis Relapsing-Remitting; Cognition; Cognition Disorders; Italy; Demography; Memory; Adult; Language; Neuropsychological Tests; SpeechmedicineHumansSpeech0501 psychology and cognitive sciencesMemory disorderCognitive deficitDemographyLanguagemedicine.diagnostic_testPatient SelectionMemoriaMultiple sclerosiscognition impairment05 social sciencesCognitive disorderNeuropsychologyCognitionNeuropsychological testmedicine.diseaserelapsing-remittingItalyinformation processing speedNeurologymultiple sclerosiSettore MED/26 - NeurologiaNeurology (clinical)medicine.symptomCognition DisordersPsychology030217 neurology & neurosurgeryrelapsing remitting
researchProduct

Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study

2021

Background and purpose: Tumefactive multiple sclerosis (TuMS) (i.e., MS onset presenting with tumefactive demyelinating lesions [TDLs]) is a diagnostic and therapeutic challenge. We performed a multicentre retrospective study to describe the clinical characteristics and the prognostic factors of TuMS. Methods: One hundred two TuMS patients were included in this retrospective study. Demographic, clinical, magnetic resonance imaging (MRI), laboratory data and treatment choices were collected. Results: TuMS was found to affect women more than men (female:male: 2.4), with a young adulthood onset (median age: 29.5 years, range: 11–68 years, interquartile range [IQR]: 38 years). At onset, 52% of …

Maletumefactive demyelinating lesions (TDLs)0302 clinical medicineRetrospective StudieInterquartile rangedifferential diagnosis030212 general & internal medicineProspective StudiesYoung adultProspective cohort studyChildtreatmentTumefactive multiple sclerosiTumefactive demyelinating lesionsDemyelinating DiseaseMiddle AgedMagnetic Resonance ImagingDifferential diagnosis Multiple sclerosis Tumefactive demyelinating lesions Tumefactive multiple sclerosisNeurologydifferential diagnosis; Multiple sclerosis; Tumefactive demyelinating lesions; Tumefactive multiple sclerosisFemaleHumanAdultmedicine.medical_specialtyMultiple SclerosisAdolescentdifferential diagnosiSettore MED/26Multiple sclerosis03 medical and health sciencesYoung AdultTumefactive multiple sclerosisOligoclonal BandInternal medicinemedicineHumansMultiple sclerosiTumefactive multiple sclerosisTumefactive multiple sclerosis (TuMS)AgedRetrospective StudiesTumefactive demyelinating lesionExpanded Disability Status Scalebusiness.industryOligoclonal BandsRetrospective cohort studyOdds ratiomedicine.diseaseConfidence intervalProspective Studiedifferential diagnosis; Multiple sclerosis; Tumefactive demyelinating lesions; Tumefactive multiple sclerosis; Adolescent; Adult; Aged; Child; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Oligoclonal Bands; Prospective Studies; Retrospective Studies; Young Adult; Demyelinating Diseases; Multiple SclerosisprognosisNeurology (clinical)business030217 neurology & neurosurgeryDemyelinating Diseases
researchProduct

Data of safety in a single-center alemtuzumab treated population

2020

Alemtuzumab is approved for highly active MS and, in Europe, can be employed after other disease-modifying treatments (DMTs) as an escalation approach or first therapeutic option. The occurrence of secondary autoimmune adverse events and infections differs depending on the employed approach.In the manuscript entitled “Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: report from a single Italian center” by di Ioia M. and collaborators, efficacy and safety data of alemtuzumab were evaluated in a real-world MS population. The aim of the article is to describe in detail the unexpected serious adverse events which occurred in this cohort during and after the administr…

Pediatricsmedicine.medical_specialtyPopulationlcsh:Computer applications to medicine. Medical informaticsSingle CenterMultiple sclerosis03 medical and health sciences0302 clinical medicinemedicinelcsh:Science (General)Adverse effecteducationAutoimmune hemolytic anemiaAlemtuzumabSecondary autoimmune disorders030304 developmental biology0303 health scienceseducation.field_of_studyMultidisciplinarybusiness.industryMultiple sclerosismedicine.diseasePancytopeniaAdverse eventsCohortlcsh:R858-859.7AlemtuzumabSettore MED/26 - NeurologiaAutoimmune hemolytic anemiaSafetybusiness030217 neurology & neurosurgerylcsh:Q1-390medicine.drugNeuroscience
researchProduct

Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: A report from a single Italian center

2020

Abstract Background Alemtuzumab, is a compound approved for highly active MS, and, in Europe, employed after the use of other disease-modifying treatments (DMTs) with an escalation approach or used as a first therapeutic option. The occurrence of secondary autoimmune adverse events and or infections can differ depending on the employed approach. Objective To evaluate the efficacy and safety of alemtuzumab in real-world MS population that encompassed patients previously treated with other DMTs. Methods 35 patients, treated with alemtuzumab in a single MS Center, were followed for at least 36 months. The study investigated the prevalence of patients reaching the phase of the non-active diseas…

AdultMalemedicine.medical_specialtyMultiple SclerosisEfficacyPopulationDisease03 medical and health sciences0302 clinical medicineInternal medicinePost-hoc analysisOutcome Assessment Health CaremedicineHumansImmunologic Factors030212 general & internal medicineAdverse effecteducationAlemtuzumabeducation.field_of_studybusiness.industryMultiple sclerosisGeneral MedicineMiddle Agedmedicine.diseasePancytopeniaProgression-Free SurvivalNeurologyItalyAdverse eventsDisease ProgressionAlemtuzumabFemaleSettore MED/26 - NeurologiaNeurology (clinical)Autoimmune hemolytic anemiaSafetybusiness030217 neurology & neurosurgerymedicine.drugFollow-Up Studies
researchProduct

Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.

2009

OBJECTIVE: Recent findings support greater efficacy of early vs. delayed interferon beta (IFNbeta) treatment in patients with a first clinical event suggestive of multiple sclerosis (MS). We aimed to evaluate the effectiveness of early IFNbeta treatment in definite relapsing-remitting MS (RRMS) and to assess the optimal time to initiate IFNbeta treatment with regard to the greatest benefits on disability progression. METHODS: A cohort of 2,570 IFNbeta-treated RRMS patients was prospectively followed for up to 7 years in 15 Italian MS Centers. A Cox proportional hazards regression model adjusted for propensity score (PS) quintiles was used to assess differences between groups of patients wit…

AdultMaleTime FactorsMultiple Sclerosis; Interferon betaInterferon-beta.Interferon betaCohort StudiesYoung AdultMultiple Sclerosis Relapsing-RemittingTreatment Outcomeobservational study multiple sclerosis interferon treatment earlySickness Impact ProfileMultiple SclerosiQuality of LifeHumansFemaleSettore MED/26 - NeurologiaProspective StudiesFollow-Up Studies
researchProduct